Older age (> 60) Renal dysfunction Type of transplant: allogeneic > autologous Pre-transplant CNS Total body irradiation High-dose conditioning regimen Acute myeloid malignancy GVHD > grade II Calcineurin inhibitor use CNS central nervous system, GVHD…
Fig. 16.1 Pulmonary complications after HSCT (borrowed from Gosselin and Adams 2002). HSCT hematopoietic stem cell transplantation 1. First, important definitions: a. Consolidation: increased attenuation of lung parenchyma with complete…
Fig. 22.1 Diffuse ground glass opacities in diffuse alveolar hemorrhage, confirmed by BAL. BAL bronchoalveolar lavage b. Pulmonary function tests (PFTs) show increased DLCO; however, often these patients cannot…
Fig. 17.1 Phases of opportunistic infections among allogeneic HSCT recipients. EBV Epstein–Barr virus, HHV-6 human herpes virus 6, PTLD posttransplant lymphoproliferative disease . © Granted by Elsevier a. Viral infections: Herpes…
Organ Clinical manifestations Histologic findings Alternate diagnoses Skin Erythematous maculopapular rash involving the palms, soles, pinnae, spreading to the trunk and later extremities. +/− pruritis. Bullae/desquamation in severe cases Basal…
NCI office of Cancer Survivorship http://cancercontrol.cancer.gov/ocs/ LiveStrong™ Foundation http://www.livestrong.org National Marrow Donor Program http://www.bethematch.org National Bone Marrow Transplant Link http://www.nbmtlink.org HSCT survivors are faced with a significantly increased risk for…
Antiemetic agent Action Dosage Side effects Anticholinergics/ antimuscarinics A direct depressant action on the VC. An antispasmodic action on the gut. Useful for motion sickness and post-operative N/V (PONV) Hyoscine…
© Springer Science+Business Media, LLC 2015Richard T. Maziarz and Susan Schubach Slater (eds.)Blood and Marrow Transplant Handbook10.1007/978-3-319-13832-9_32 32. Posttransplant Relapse Marlise R. Luskin1 and David L. Porter1 (1) Division of Hematology/Oncology and the Abramson Cancer Center, Perelman…
Type of product TNC/kg body weight of recipient CD34 + cell/kg body weight of recipient Bone marrow > 2 × 108 Peripheral blood stem cells > 2 × 108 > 3 × 106 Double cord blood—each unit > 2 × 107 …
Alkylating agents Topoisomerase II inhibitors Latency 3–8 years 2–3 years Incidence 2–20 % 2–12 % Myelodysplastic phase Present Absent FAB type M1, M2 M4, M5 Cytogenetics 5-, 7-, 5q-, 7q- 11q23…
